Pravastatin Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug:  Lovastatin Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition:   Hypercholesterolaemia Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3  fatty acids;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2018 Category: Research Source Type: clinical trials